Third consensus on medical treatment of metastatic breast cancer (2009)
Beslija, S., Bonneterre, J., Burstein, H. J., Cocquyt, V., Gnant, M., Heinemann, V., ...
Background: Treatment options for patients with metastatic breast cancer (MBC) include a rapidly expanding repertoire of medical, surgical and supportive care measures. Design: To provide timely and...
Boeck, S., Hoehler, T., Seipelt, G., Mahlberg, R., Wein, A., Hochhaus, A., ...
Background: To compare the efficacy and safety of three different chemotherapy doublets in the treatment of advanced pancreatic cancer (PC). Patients and methods: At total of 190 patients were...
Heinemann, V., Labianca, R., Hinke, A., Louvet, C.
Background: The aim was to evaluate the efficacy of gemcitabine combined with a platinum agent compared to single-agent gemcitabine in a pooled analysis of two randomized trials. Methods: The French...
Lorenzen, S., Hentrich, M., Haberl, C., Heinemann, V., Schuster, T., Seroneit, T., ...
Background: Phase II and III trials of docetaxel, cisplatin and fluorouracil (DCF) have shown superior efficacy versus cisplatin and fluorouracil alone but high rates of hematologic toxicity in...
Verslype, C, Van Cutsem, E, Dicato, M, Cascinu, S, Cunningham, D, Diaz-Rubio, E, ...
This article summarizes the expert discussion on the management of pancreatic cancer, which took place during the 8th World Congress on Gastrointestinal Cancer in June 2006 in Barcelona. A...
Boeck, S, Weigang-Köhler, K, Fuchs, M, Kettner, E, Quietzsch, D, Trojan, J, ...
Background: A standard second-line chemotherapy regimen has yet to be defined for patients with gemcitabine (Gem)-refractory advanced pancreatic cancer (PC). Patients and methods: In this multicenter...
Second consensus on medical treatment of metastatic breast cancer (2007)
BESLIJA, S, BONNETERRE, J, BURSTEIN, H, Cocquyt, Veronique, GNANT, M, GOODWIN, P, ...
Boeck, S, Weigang-Köhler, K, Fuchs, M, Kettner, E, Quietzsch, D, Trojan, J, ...
Background: A standard second-line chemotherapy regimen has yet to be defined for patients with gemcitabine (Gem)-refractory advanced pancreatic cancer (PC). Patients and methods: In this multicenter...
Second consensus on medical treatment of metastatic breast cancer (2007)
Beslija, S, Bonneterre, J, Burstein, H, Cocquyt, V, Gnant, M, Goodwin, P, ...
The present consensus manuscript defines evidence-based recommendations for state-of-the-art treatment of metastatic breast cancer depending on disease-associated and biologic variables.
Boeck, S, Weigang-Köhler, K, Fuchs, M, Kettner, E, Quietzsch, D, Trojan, J, ...
Background: A standard second-line chemotherapy regimen has yet to be defined for patients with gemcitabine (Gem)-refractory advanced pancreatic cancer (PC). Patients and methods: In this multicenter...
Stemmler, H J, Schmitt, M, Harbeck, N, Willems, A, Bernhard, H, Lässig, D, ...
Leptomeningeal carcinomatosis represents a rare manifestation of metastatic breast cancer (MBC). A 39-year-old female presenting with HER2-overexpressing MBC and suffering from meningeal...
Second consensus on medical treatment of metastatic breast cancer (2006)
Beslija, S., Bonneterre, J., Burstein, H., Cocquyt, V., Gnant, M., Goodwin, P., ...
The present consensus manuscript defines evidence-based recommendations for state-of-the-art treatment of metastatic breast cancer depending on disease-associated and biologic variables.
Second consensus on medical treatment of metastatic breast cancer (2006)
Beslija, S., Bonneterre, J., Burstein, H., Cocquyt, V., Gnant, M., Goodwin, P., ...
The present consensus manuscript defines evidence-based recommendations for state-of-the-art treatment of metastatic breast cancer depending on disease-associated and biologic variables.
Gastrointestinal toxicity associated with weekly docetaxel treatment (2002)
Stemmler, H. J., Kenngott, S., Diepolder, H., Heinemann, V.
Previous studies have demonstrated a marked reduction of haematological and non-haematological toxicity if weekly doses of docetaxel
Weekly docetaxel (Taxotere(R)) in patients with metastatic breast cancer (2001)
Stemmler, H. J., Gutschow, K., Sommer, H., Malekmohammadi, M., Kentenich, Ch., Forstpointner, R., ...
Background: Docetaxel (Taxotere®) has demonstrated high antitumour activity in first- and second-line treatment of metastatic breast cancer. This study analysed the efficacy and toxicity of...
Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer (2000)
Heinemann, V., Wilke, H., Clemens, M., König, H., Illiger, H. J., ...
Background This phase II study was initiated to determine the efficacy and safety of gemcitabine plus cisplatin in patients with pancreatic cancer. Patients and methods Gemcitabine 1000 mg/m2 was...
Heinemann, V, Bosse, D, Jehn, U, Debus, A, Wachholz, K, Forst, H, ...
Strohscheer, I., Kleinert, R., Westphal, C., Schüller, J., Werner, K., Anders, O., ...
Peer Reviewed
Serum pharmacology of amphotericin B applied in lipid emulsions.
Heinemann, V, Kähny, B, Jehn, U, Mühlbayer, D, Debus, A, Wachholz, K, ...
Application of amphotericin B in lipid emulsions (AmB/L) reduced membrane toxicity in vitro and decreased amphotericin B-associated toxic side effects in vivo when compared to that of amphotericin B...
Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients.
Heinemann, V, Bosse, D, Jehn, U, Kähny, B, Wachholz, K, Debus, A, ...
The liposomal formulation of amphotericin B (AmBisome) greatly reduces the acute and chronic side effects of the parent drug. The present study describes the pharmacokinetic characteristics of...
Serum pharmacology of amphotericin B applied in lipid emulsions.
Heinemann, V, Kähny, B, Jehn, U, Mühlbayer, D, Debus, A, Wachholz, K, ...
Application of amphotericin B in lipid emulsions (AmB/L) reduced membrane toxicity in vitro and decreased amphotericin B-associated toxic side effects in vivo when compared to that of amphotericin B...
Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients.
Heinemann, V, Bosse, D, Jehn, U, Kähny, B, Wachholz, K, Debus, A, ...
The liposomal formulation of amphotericin B (AmBisome) greatly reduces the acute and chronic side effects of the parent drug. The present study describes the pharmacokinetic characteristics of...